Insights

• Shah, Unmesh; Lankin, Claire M.; Boyle, Craig D.*; Chackalamannil, Samuel; et al., “Design, Synthesis, and Evaluation of Fused Heterocyclic Analogs of SCH 58261 as Adenosine A2A Receptor Antagonists”; Med. Chem. Lett. 2008, 18, 4204.
• Shah, Unmesh; Boyle, Craig D.*; Chackalamannil, Samuel; et al., “Biaryl and Heteroaryl Derivatives of SCH 58261 as Potent and Selective Adenosine A2A Receptor Antagonists”; Med. Chem. Lett. 2008, 18, 4199.
• Boyle, Craig D.*, “Recent Advances in the Discovery of 11b-HSD1 Inhibitors”; Opin. Drug Discov. Devel. 2008, 11, 495: invited review.
• Boyle, Craig D.*; Kowalski, Timothy J.; Zhang, Lili, “11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitors”; Rep. Med. Chem. 2006, 41, 127: invited review.
• Boyle, Craig D.*; Xu, Ruo*; et al., “Optimization of a Purine Based PDE1/PDE5 Inhibitor to a Potent and Selective PDE5 Inhibitor for the Treatment of Male ED”; Med. Chem. Lett. 2005, 15, 2365.
• Pissarnitski, Dmitri A.*; Boyle, Craig D.; et al., “SAR Development of Polycyclic Guanine Derivatives Targeted to the Discovery of a Selective PDE5 Inhibitor for Treatment of Erectile Dysfunction”; Med. Chem. Lett. 2004, 14, 1291.
• Boyle, Craig D.; Palani, Anandan, “Structure-Activity Relationship Studies: M2 and CCR5 Receptor Antagonists”; Top. Med. Chem. 2003, 3, 1155: invited review.
• Wang, Yuguang*; Boyle, Craig D.; et al., “Improving the Oral Efficacy of CNS Drug Candidates: Discovery of Highly Orally Efficacious Piperidinyl Piperidine M2 Muscarinic Receptor Antagonists”; Med. Chem. 2002, 45, 5415.
• Boyle, Craig D.*; Vice, Susan; et al., “Enhancement of Pharmacokinetic Properties and In Vivo Efficacy of Benzylidene Ketal M2 Muscarinic Receptor Antagonists via Benzamide Modification”; Med. Chem. Lett. 2002, 12, 3479.
• Wang, Yuguang*; Boyle, Craig D.; et al., “Design and Synthesis of Xanthine Analogues as Potent and Selective PDE5 Inhibitors”; Med. Chem. Lett. 2002, 12, 3149.
• Boyle, Craig D.*; Lachowicz, Jean E., “Orally Active and Selective Benzylidene Ketal M2 Muscarinic Receptor Antagonists for the Treatment of Alzheimer’s Disease”; Drug Dev. Res. 2002, 56, 310: invited review.
• Tagat, Jayaram R.*; Boyle, Craig D.; et al., “Synthesis of Mono- and Difluoronaphthoic Acids”; Org. Chem. 2002, 67, 1171.
• Boyle, Craig D.*; Chackalamannil, Samuel; et al., “Metabolic Stabilization of Benzylidene Ketal M2 Muscarinic Receptor Antagonists via Halonaphthoic Acid Substitution”; Med. Chem. Lett. 2001, 11, 2311.
• Boyle, Craig D.*; Chackalamannil, Samuel; et al., “Benzylidene Ketals as M2 Muscarinic Receptor Antagonists”; Med. Chem. Lett. 2000, 10, 2727.
• Boyle, Craig D.; Kishi, Yoshito*, “Absolute Configuration at the Tricarballylic Acid Moieties of Fumonisin B1 and AAL Toxin TA”; Tetrahedron Lett. 1995, 36,
• Boyle, Craig D.; Kishi, Yoshito*, “Absolute Configuration at the Tricarballylic Acid Moieties of Fumonisin B2”; Tetrahedron Lett. 1995, 36,
• Harmange, Jean-Christophe; Boyle, Craig D.; Kishi, Yoshito*, “Relative and Absolute Stereochemistry of the Fumonisin B2 Backbone”; Tetrahedron Lett. 1994, 35,
• Boyle, Craig D.; Harmange, Jean-Christophe; Kishi, Yoshito*, “Novel Structure Elucidation of AAL Toxin TA Backbone”; J. Am. Chem. Soc. 1994, 116, 4995.

Speaking engagements

• Neelamkavil, Santhosh F.*; Boyle, Craig D.; et al., “Pyridopyrimidinone Analogs as Orally Efficacious GPR119 Agonists”; Abstracts of Papers, 243rd American Chemical Society National Meeting, San Diego, CA, March 25-29, 2012; Division of Medicinal Chemistry Poster Abstract 423.
• Shah, Unmesh*; Boyle, Craig D.; et al., “Discovery of Structurally Distinct Analogs of SCH 420814 (Preladenant) as Adenosine A_2AReceptor Antagonists”; Abstracts of Papers, 239^th American Chemical Society National Meeting, San Francisco, CA, March 21-25, 2010; Division of Medicinal Chemistry Oral Poster Abstract 547.
• Neelamkavil, Santhosh F.*; Boyle, Craig D.; et al., “Discovery of a Potent and Orally Efficacious Agonist of the G-protein Coupled Receptor 119”; Abstracts of Papers, 239th American Chemical Society National Meeting, San Francisco, CA, March 21-25, 2010; Division of Medicinal Chemistry Poster Abstract 182.
• Shah, Unmesh*; Boyle, Craig D.; et al., “Design, Synthesis, and Evaluation of Fused Heterocyclic Analogs as Adenosine A2A Receptor Antagonists”; Abstracts of Papers, 235th American Chemical Society National Meeting, New Orleans, LA, April 6-10, 2008; Division of Medicinal Chemistry Oral Poster Abstract 179.
• Neelamkavil, Santhosh F.*; Boyle, Craig D.; et al., “Synthesis and Biologic Evaluation of Selective Inhibitors of 11b-HSD1 as a Potential Treatment for Metabolic Disorders”; Abstracts of Papers, 234th American Chemical Society National Meeting, Boston, MA, August 19-23, 2007; Division of Medicinal Chemistry Poster Abstract 53.
• Lankin, Claire M.*; Boyle, Craig D.; et al., “Discovery and SAR of Novel Derivatives as 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitors”; Abstracts of Papers, 234th American Chemical Society National Meeting, Boston, MA, August 19-23, 2007; Division of Medicinal Chemistry Poster Abstract 52.
• Shah, Unmesh*; Boyle, Craig D.; et al., “Novel Analogs as 11b-HSD1 Inhibitors”; Abstracts of Papers, 234th American Chemical Society National Meeting, Boston, MA, August 19-23, 2007; Division of Medicinal Chemistry Poster Abstract 49.
• Boyle, Craig D.*; et al., “Biaryl and Heteroaryl Derivatives of SCH 58261 as Potent and Selective Adenosine A2A Receptor Antagonists”; Abstracts of Papers, AMRI Frontiers in Drug Discovery Symposium, Albany, NY, October 5-6, 2006.
• Boyle, Craig D.*; et al., “Biaryl and Heteroaryl Derivatives of SCH 58261 as Potent and Selective Adenosine A2A Receptor Antagonists”; Abstracts of Papers, Targeting Adenosine A2A Receptors in Parkinson’s Disease and Other CNS Disorders, Boston, MA, May 17-19, 2006; Poster Abstract 1.
• Shah, Unmesh*; Boyle, Craig D.; et al., “Biaryl and Heteroaryl Derivatives of SCH 58261 as Potent and Selective Adenosine A2A Receptor Antagonists”; Abstracts of Papers, 230th American Chemical Society National Meeting, Washington, DC, August 28-September 1, 2005; Division of Medicinal Chemistry Poster Abstract 76.
• Boyle, Craig D.*; et al., “Discovery of a PDE5 Inhibitor for the Treatment of Male ED”; Abstracts of Papers, 227th American Chemical Society National Meeting, Anaheim, CA, March 28-April 1, 2004; Division of Medicinal Chemistry Oral Paper Abstract 12; part of “First-Time Disclosures of Clinical Candidates” symposium. Featured in C&E News: May 10, 2004; 82(19); p. 43.
• Boyle, Craig D.*; “Piperidino Piperidine M2 Muscarinic Receptor Antagonists for the Treatment of Alzheimer’s Disease”; Invited Guest Lecture, Columbia University Department of Medicine, February 19, 2004.
• Wang, Yuguang*; Chackalamannil, S.; Boyle, Craig D.; et al., “The Discovery of Sch 444877, A Potent, Selective and Orally Active Cyclic Guanine PDE5 Inhibitor”; Abstracts of Papers, 226th American Chemical Society National Meeting, New York, NY, September 7-11, 2003; Division of Medicinal Chemistry Oral Paper Abstract 367.
• Boyle, Craig D.*; et al., “Piperidino Piperidine M2 Muscarinic Receptor Antagonists for the Treatment of Alzheimer’s Disease”; Abstracts of Papers, 225th American Chemical Society National Meeting, New Orleans, LA, March 23-27, 2003; Division of Medicinal Chemistry Oral Paper Abstract 332; part of “Subtype Selective Muscarinic Receptor Ligands” symposium: invited lecture.
• Boyle, Craig D.*; Lankin, Claire*; et al., “2,4-Diarylimidazoles as Neuropeptide Y Y5 Receptor Antagonists”; Abstracts of Papers, 224th American Chemical Society National Meeting, Boston, MA, August 18-22, 2002; Division of Medicinal Chemistry Poster Abstract 335.
• Boyle, Craig D.*, “Pharmacokinetic Improvement of Benzylidene Ketal M2 Muscarinic Receptor Antagonists via Aryl Amide Modification”; 4th Annual Cambridge Healthtech Institute Smarter Lead Optimization Conference, Philadelphia, PA, May 6-8, 2002: invited lecture.
• Boyle, Craig D.*; Chackalamannil, Samuel; et al., “Pharmacokinetic Improvement of Benzylidene Ketal M2 Muscarinic Receptor Antagonists via Aryl Amide Modification”; Abstracts of Papers, 222nd American Chemical Society National Meeting, Chicago, IL, August 26-30, 2001; Division of Medicinal Chemistry Oral Paper Abstract 11.
• Boyle, Craig D.*; Chackalamannil, Samuel; et al., “Benzylidene Ketal Derivatives as M2 Muscarinic Receptor Antagonists”; Abstracts of Papers, 220th American Chemical Society National Meeting, Washington, DC, August 20-24, 2000; Division of Medicinal Chemistry Poster Abstract 114.
• Tagat, J. R.*; McCombie, S. W.; Nazareno, D. V.; Kozlowski, J. A.; Boyle, C.; Josien, H.; Wang, Y.; Zhou, G., “Synthesis of Mono- and Difluoro-1-Naphthoic Acids”; Abstracts of Papers, 36th National Organic Chemistry Symposium, Madison, WI, 1999; Abstract 259.